Biofilms are a major underlying factor in chronic infections, antimicrobial resistance (AMR), and oral diseases such as gingivitis and periodontitis. By directly targeting biofilm structures, ZymIQ's technology introduces a fundamentally different approach to conventional antimicrobial treatments. 

The Japanese patent builds on an expanding international IP portfolio, including a granted European patent with Unitary Patent coverage, validation in the United Kingdom, and protection in Hong Kong. Additional applications are progressing in multiple jurisdictions worldwide. 

The technology enables both prevention of biofilm formation and active degradation of existing microbial deposits. Stabilized for use under physiological conditions, it is adaptable across sprays, gels, and oral care formats, supporting commercialization across medical and consumer health markets. 

Japan is a strategically important future market for ZymIQ, given its leadership in healthcare innovation and oral care. Patent protection in the region strengthens the company's ability to pursue partnerships, licensing agreements, and market entry across Asia. 

ZymIQ's platform underpins a growing pipeline targeting oral health, dermatology, wound care, and veterinary applications. 

"Japan is a future key market for us, and this patent is another step in building the IP foundation our platform deserves," said Michael Edelborg Christensen, CEO of ZymIQ Technology. "Enzyme-based solutions will become the new standard in managing biofilm-driven infections globally."